Advertisement
Screener

CRESCENT BIOPHARMA, INC. (CBIO) Graph

CBIO Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2015-06-30: Revenue $20.00M; Revenue including tax $20.00M.
  • 2014-05-31: Revenue $15.00M; Revenue including tax $15.00M.

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

CBIO revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Reportable Segment$0.00Revenue$0.00Operating expenses$28.13MOperating income-$26.36MOther income, net$1.53MResearch & development$19.39MIncome tax$0.00

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 1 month

Period endRevenueRevenue including tax
2015-06-30$20.00M$20.00M
2014-05-31$15.00M$15.00M

Revenue and expense 3 month

Period endRevenueRevenue including taxResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$0.00(m)$19.39M(m)$28.13M$0.00-$24.84M
2026-03-31$1.04M(m)$17.90M(m)$25.77M$0.00-$23.28M
2025-12-31(m)(m)$95.03M*(m)$102.34M*$2.00M*-$23.30M
2025-09-30(m)(m)$20.35M(m)$25.89M$0.00-$24.61M
2025-06-30$0.00(m)$12.08M(m)$21.03M$0.00-$21.79M
2025-03-31$0.00(m)$10.63M(m)$14.22M$0.00-$15.15M
2024-12-31$0.00(m)$14.03M(m)$17.19M$0.00-$17.87M
2024-09-30(m)(m)$1.72M(m)$11.23M(m)-$9.82M
2024-06-30(m)(m)$6.29M(m)$10.36M(m)-$10.10M
2024-03-31(m)(m)$6.03M(m)$11.12M(m)-$10.74M
2023-09-30(m)(m)$5.29M(m)$9.81M(m)-$9.20M
2023-06-30(m)(m)$4.07M(m)$8.93M(m)-$8.26M
2023-03-31(m)(m)$5.42M(m)$10.94M(m)-$10.36M
2022-09-30(m)(m)$4.92M(m)$8.77M(m)-$8.52M
2022-06-30(m)$75.00K$7.97M(m)$13.43M(m)-$13.27M
2022-03-31(m)(m)$9.60M(m)$14.66M(m)-$14.65M
2021-09-30(m)$86.56K$13.28M(m)$17.42M(m)-$17.33M
2021-06-30(m)$142.00$10.17M(m)$14.40M(m)-$14.40M
2021-03-31(m)$1.06M$11.15M(m)$15.34M(m)-$14.27M
2020-09-30(m)$1.00M$10.67M(m)$14.73M(m)-$13.72M
2020-06-30(m)(m)$9.87M(m)$14.11M(m)-$14.08M
2020-03-31(m)$9.00M$12.67M(m)$17.11M(m)-$7.66M
2019-12-31(m)(m)(m)(m)(m)(m)-$14.73M
2019-09-30(m)(m)$10.72M(m)$14.11M(m)-$13.25M
2019-06-30(m)(m)$13.07M(m)$16.82M(m)-$15.83M
2019-03-31(m)(m)$11.77M(m)$15.13M(m)-$14.08M
2018-12-31(m)(m)(m)(m)(m)(m)-$13.91M
2018-09-30(m)(m)$9.73M(m)$12.52M(m)-$11.58M
2018-06-30(m)(m)$9.30M(m)$12.15M(m)-$11.28M
2018-03-31(m)(m)$9.30M(m)$12.15M(m)-$11.51M
2017-12-31(m)(m)(m)(m)(m)(m)-$9.26M
2017-09-30(m)(m)$5.78M(m)$8.18M(m)-$7.95M
2017-06-30(m)(m)$5.72M(m)$8.24M(m)-$8.14M
2017-03-31(m)(m)$5.88M(m)$7.97M(m)-$7.93M
2016-12-31(m)(m)(m)(m)(m)(m)-$8.33M
2016-09-30$18.50K(m)$5.92M(m)$7.91M(m)-$7.85M
2016-06-30(m)(m)$5.78M(m)$8.09M(m)-$8.07M
2016-03-31(m)(m)$5.52M(m)$7.58M(m)-$7.55M
2015-12-31$35.38K(m)(m)(m)(m)(m)-$8.88M
2015-09-30(m)(m)$5.04M(m)$7.17M(m)-$7.17M
2015-06-30$20.04M(m)$7.84M(m)$9.65M(m)$10.39M
2015-03-31$0.00(m)$5.21M(m)(m)$0.00-$7.11M
2014-12-31(m)(m)(m)$2.12M*(m)(m)-$7.39M
2014-09-30(m)(m)$5.05M$1.65M(m)-$76.76K-$6.62M
2014-06-30$15.03M(m)$5.36M$1.61M(m)$76.76K$7.99M
2014-03-31$0.00(m)$3.88M$1.22M(m)$0.00-$5.10M
2013-12-31$77.41K(m)(m)(m)(m)(m)-$3.87M
2013-09-30$52.57K(m)$2.95M$800.23K(m)$0.00-$3.70M
2013-06-30$55.07K(m)$2.88M$668.25K(m)(m)-$3.50M
2013-03-31$3.81M(m)$2.74M$605.94K(m)(m)$459.69K

Revenue and expense 6 month

Period endRevenueRevenue including taxResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$1.04M(m)$37.29M(m)$53.90M$0.00-$48.12M
2025-06-30$0.00(m)$22.71M(m)$35.26M$0.00-$36.94M
2024-06-30(m)(m)$12.31M(m)$21.47M(m)(m)
2023-06-30(m)(m)$9.49M(m)$19.87M(m)(m)
2022-06-30(m)$75.00K$17.58M(m)$28.09M(m)(m)
2021-06-30(m)$1.06M$21.31M(m)$29.74M(m)(m)
2020-06-30(m)$9.00M$22.54M(m)$31.21M(m)-$21.74M
2019-06-30(m)(m)$24.84M(m)$31.95M(m)-$29.91M
2018-06-30(m)(m)$18.32M(m)$24.03M(m)-$22.79M
2017-06-30(m)(m)$11.60M(m)$16.21M(m)-$16.07M
2016-06-30(m)(m)$11.30M(m)$15.67M(m)-$15.63M
2015-06-30$20.04M(m)$13.05M(m)$16.76M$0.00$3.28M
2014-06-30$15.03M(m)$9.24M$2.83M(m)$76.76K$2.89M
2013-06-30$3.86M(m)$5.63M$1.27M(m)$0.00-$3.04M

Revenue and expense 9 month

Period endRevenueRevenue including taxResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-09-30(m)(m)$43.06M(m)$61.14M$0.00-$61.55M
2024-09-30(m)(m)$14.03M(m)$32.71M(m)(m)
2023-09-30(m)(m)$14.78M(m)$29.68M(m)(m)
2022-09-30(m)$75.00K$22.50M(m)$36.86M(m)(m)
2021-09-30(m)$1.14M$34.60M(m)$47.16M(m)(m)
2020-09-30(m)$10.00M$33.21M(m)$45.94M(m)-$35.46M
2019-09-30(m)(m)$35.56M(m)$46.05M(m)-$43.17M
2018-09-30(m)(m)$28.05M(m)$36.54M(m)-$34.37M
2017-09-30(m)(m)$17.38M(m)$24.40M(m)-$24.02M
2016-09-30$18.50K(m)$17.22M(m)$23.57M(m)-$23.48M
2015-09-30$20.04M(m)$18.09M(m)$23.93M(m)-$3.89M
2014-09-30$15.03M(m)$14.29M$4.48M(m)$0.00-$3.73M
2013-09-30$3.92M(m)$8.58M$2.07M(m)$0.00-$6.74M

Revenue and expense 12 month

Period endRevenueRevenue including taxResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$10.84M(m)$138.09M(m)$163.48M$2.00M$153.94K
2024-12-31(m)(m)$14.26M(m)$40.04M(m)$37.88K
2023-12-31(m)$10.00K$20.07M(m)$39.29M(m)$36.90K
2022-12-31(m)$75.00K$28.39M(m)$47.48M(m)-$46.69M
2021-12-31(m)$1.16M$47.49M(m)$64.61M(m)-$63.43M
2020-12-31(m)$10.16M$44.93M(m)$61.67M(m)-$51.03M
2019-12-31(m)(m)$47.03M(m)$61.39M(m)-$57.89M
2018-12-31(m)(m)$40.09M(m)$51.50M(m)-$48.27M
2017-12-31(m)(m)$24.10M(m)$33.93M(m)-$33.28M
2016-12-31$18.50K$18.50K$23.28M(m)$31.93M(m)-$31.81M
2015-12-31$20.07M(m)$25.05M(m)$32.86M(m)-$12.77M
2014-12-31$15.03M(m)$19.57M$6.60M$26.17M(m)-$11.12M
2013-12-31$3.99M(m)$11.70M$2.90M(m)(m)-$10.61M
2012-12-31$15.26M(m)$9.44M$2.18M(m)(m)$3.66M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
Evolus, Inc. (EOLS)United States$0.519B-13.32
ARVINAS, INC. (ARVN)United States$0.510B58.38
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Altimmune, Inc. (ALT)United States$0.593B-6.43
Monopar Therapeutics (MNPR)United States$0.598B-34.82